TLC President On COVID, Cross-Strait Taiwan Tensions
Trial Flexibility Another Key Issue
A recent survey showed healthcare as the sector US public companies were most concerned about (after semiconductors) amid the ongoing China-US tensions over Taiwan. But how do biotech firms in Taiwan itself view the current situation? Scrip spoke to the president of one of the most innovative and active companies in the sector, amid the island’s imminent reopening to the world after over two long years under pandemic restrictions.
You may also be interested in...
The hard going could get even tougher as a funding crunch continues for China’s biotech sector, which is being hit by a paradox that could see more pain ahead, leading investors to take the pulse of the sector as the Year of the Rabbit starts.
From orphan to cancer drugs, more products have had their prices cut in the latest round of reimbursement negotiations in China. Although the 60% average across 100 medicines was considered mild given it didn’t go beyond the previous year, it was still chilling and is prompting more firms, both multinational and domestic, to walk away from the process.
For the first time in 61 years, China has reported its population is shrinking and the new demographic shift is likely to have a far-reaching impact on the pharma sector. Meanwhile, regulators have accelerated the approval of new COVID-19 drugs to relieve acute shortages.